News | Artificial Intelligence | July 10, 2020

Infervision's newly FDA approved CT lung AI application sets a new standard

Infervision's newly FDA approved CT lung AI application sets a new standard

July 10, 2020 — Infervision announced U.S. Food and Drug Administration (FDA) 510(K) clearance of the InferRead Lung CT.AI product, which uses the state-of-the-art artificial intelligence and deep learning technology to automatically perform lung segmentation, along with accurately identifying and labeling nodules of different types. InferRead Lung CT.AI is designed to support concurrent reading and can aid radiologists in pulmonary nodule detection during the review of chest computed tomography (CT) scans, increasing accuracy and efficiency.  With five years of international clinical use, Infervision's InferRead Lung CT.AI application is a robust and powerful tool to assist the radiologist.

InferRead Lung CT.AI is currently in use at over 380 hospitals and imaging centers globally. More than 55,000 cases daily are being processed by the system and over 19 million patients have already benefited from this advanced AI technology. "Fast, workflow friendly, and accurate are the three key areas we have emphasized during product development. We're very excited to be able to make our InferRead Lung CT.AI solution available to the North American market. Our clients tell us it has great potential to help provide improved outcomes for providers and patients alike," said Matt Deng, Ph.D., Director of Infervision North America. The Company offers the system under a number of pricing models to make it easy to acquire.

The company predicts the system may also be of great benefit to lung cancer screening (LCS) programs across the nation. Lung cancer is the second most common cancer in both men and women in the U.S. Survival rates are 60% in five years if discovered at an early stage. However, the survival rate is lower than 10% if the disease progresses to later stages without timely follow-up and treatment. The Lung Cancer Screening program has been designed to encourage the early diagnosis and treatment of the high-risk population meeting certain criteria. The screening process involves Low-dose CT (LDCT) scans to determine any presence of lung nodules or early-stage lung disease. However small nodules can be very difficult to detect and missed diagnoses are not uncommon.

"The tremendous potential for lung cancer screening to reduce mortality in the U.S. is very much unrealized due to a combination of reasons.  Based on our experience reviewing the algorithm for the past several months and my observations of its extensive use and testing internationally, I believe that Infervision's InferRead Lung CT.AI application can serve as a robust lung nodule "spell-checker" with the potential to improve diagnostic accuracy, reduce reading times, and integrate with the image review workflow," said Eliot Siegel, M.D., Professor and Vice Chair of research information systems in radiology at the University of Maryland School of Medicine.

InferRead Lung CT.AI is now FDA cleared, and has also received the CE mark in Europe. "This is the first FDA clearance for our deep-learning-based chest CT algorithm and it will lead the way to better integration of advanced A.I. solutions to help the healthcare clinical workflow in the region," according to Deng. "This marks a great start in the North American market, and we are expecting to provide more high-performance AI tools in the near future."

For more information: global.infervision.com

Related Content

News | Ultrasound Imaging

June 28, 2022 — Mindray, a global leader and developer of healthcare technologies and solutions for ultrasound, patient ...

Time June 28, 2022
arrow
News | Cardiac Imaging

June 24, 2022 — The Radiological Society of North America (RSNA) reports that Coronary Artery Calcium (CAC) scoring with ...

Time June 24, 2022
arrow
News | Lung Imaging

June 24, 2022 — Xoran Technologies announced they have begun work on Phase 2 of their mobile lung grant with the goal to ...

Time June 24, 2022
arrow
News | Radiation Therapy

June 23, 2022 — RaySearch Laboratories AB announced the release of the latest version of RayCare*, the next generation ...

Time June 23, 2022
arrow
News | Radiology Business

June 22, 2022 — Blackford, a medical imaging AI platform leader that helps healthcare professionals add clinical value ...

Time June 22, 2022
arrow
News | Radiation Therapy

June 17, 2022 — Accuray Incorporated and Limbus AI Inc. announced they are partnering to augment Accuray adaptive ...

Time June 17, 2022
arrow
News | Computed Tomography (CT)

June 16, 2022 — Xoran Technologies has recently received a patent for a modular computed tomography (CT) system assembly ...

Time June 16, 2022
arrow
News | Artificial Intelligence

June 14, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), incorporating AI support into clinical ...

Time June 14, 2022
arrow
News | PET-CT

June 14, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and ...

Time June 14, 2022
arrow
News | SPECT-CT

June 13, 2022 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Symbia Pro ...

Time June 13, 2022
arrow
Subscribe Now